Effects of anacetrapib on plasma lipids, apolipoproteins and PCSK9 in healthy, lean rhesus macaques

European Journal of Pharmacology

Volumn 740, Issue , 2014, Pages 410-416

  Roddy, Thomas P ^a   McLaren, David G ^a   Chen, Ying ^a   Xie, Dan ^a   Dunn, Keiana ^a   Kulick, Alison ^a   Szeto, Daphne ^a   Forrest, Gail ^a   Albanese, Kelly ^a   Donnelly, Marcie ^a   Gai, Cesaire ^a   Gewain, Andrew ^a   Lederman, Harmony ^a   Jensen, Kristian K ^a   Ai, Xi ^a   Vachal, Petr ^a   Akinsanya, Karen O ^a   Cleary, Michele A ^a   Previs, Stephen F ^a   Dansky, Hayes M ^a   Johns, Douglas G ^a   more..

^a MERCK RESEARCH LABORATORIES   (United States)

Author keywords

Anacetrapib; Cholesteryl ester transfer protein; Lipoproteins PCSK9; Rhesus macaques

Indexed keywords

ANACETRAPIB; APOLIPOPROTEIN A1; APOLIPOPROTEIN B; APOLIPOPROTEIN E; CHOLESTEROL ESTER TRANSFER PROTEIN; CHYLOMICRON REMNANT; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; LIPID; LOW DENSITY LIPOPROTEIN CHOLESTEROL; MEMBRANE PROTEIN; PCSK9 PROTEIN; UNCLASSIFIED DRUG; APOLIPOPROTEIN; HYPOCHOLESTEROLEMIC AGENT; OXAZOLIDINONE DERIVATIVE; SERINE PROTEINASE; TRIACYLGLYCEROL;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIHYPERLIPIDEMIA ACTIVITY; ARTICLE; CONCENTRATION RESPONSE; CONTROLLED STUDY; DOWN REGULATION; DRUG ACTIVITY; DRUG MECHANISM; FRACTIONATION; HYPERLIPIDEMIA; LIPID BLOOD LEVEL; LIQUID CHROMATOGRAPHY; MALE; NONHUMAN; PROTEIN BLOOD LEVEL; PROTEIN DETERMINATION; PROTEIN FUNCTION; RHESUS MONKEY; UPREGULATION; ANIMAL; ANTAGONISTS AND INHIBITORS; BLOOD;

ANIMALS; ANTICHOLESTEREMIC AGENTS; APOLIPOPROTEINS; CHOLESTEROL ESTER TRANSFER PROTEINS; CHOLESTEROL, HDL; CHOLESTEROL, LDL; MACACA MULATTA; MALE; OXAZOLIDINONES; PROPROTEIN CONVERTASES; SERINE ENDOPEPTIDASES; TRIGLYCERIDES;

EID: 84919439236     PISSN: 00142999     EISSN: 18790712     Source Type: Journal    
DOI: 10.1016/j.ejphar.2014.04.015     Document Type: Article

References (20)

1. P.J. Barter, M. Caulfield, M. Eriksson, S.M. Grundy, J.J.P. Kastelein, M. Komajda, J. Lopez-Sendon, L. Mosca, J.-C. Tardif, D.D. Waters, C.L. Shear, J.H. Revkin, K.A. Buhr, M.R. Fisher, A.R.T. Tall, and B. Brewer Effects of torcetrapib in patients at high risk for coronary events N. Engl. J. Med. 357 2007 2109 2122
2. Barylski M.; Toth P.P.; Nikolic D.; Banach M.; Rizzo M.; Montalto G.; Emerging therapies for raising high-density lipoprotein cholesterol (HDL-C) and augmenting HDL particle functionality, Best Pract. Res. Clin. Endocrinol. Metab.; 10.1016/j.beem.2013.11.001, in press
3. D. Bloomfield, G.L. Carlson, A. Sapre, D. Tribble, J.M. McKenney, T.W. Littlejohn, C. McCrary, Y. Mitchel, and R.C. Pasternak Efficacy and safety of the cholesteryl ester transfer protein inhibitor anacetrapib as monotherapy and coadministered with atorvastatin in dyslipidemic patients Am. Heart J. 157 2009 352 360
4. C.P. Cannon, S. Shah, H.M. Dansky, M. Davidson, E.A. Brinton, A.M. Gotto Jr.; M. Stepanavage, S.X. Liu, P. Gibbons, T.B. Ashraf, J. Zafarino, Y. Mitchel, and P.J. Barter Safety of anacetrapib in patients with or at high risk for coronary heart disease N. Engl. J. Med. 363 2010 2406 2415
5. J. Castro-Perez, F. Briand, K. Gagen, S.-P. Wang, Y. Chen, D.G. McLaren, V. Shah, R.J. Vreeken, T. Hankemeier, T. Sulpice, T.P. Roddy, B.K. Hubbard, and D.G. Johns Anacetrapib promotes reverse cholesterol transport and bulk cholesterol excretion in Syrian golden hamsters J. Lipid Res. 52 2011 1965 1973
6. B. Dahlof Cardiovascular disease risk factors: epidemiology and risk assessment Am. J. Cardiol. 105 2010 3A 9A
7. M. Frank-Kamenetsky, A. Grefhorst, N.N. Anderson, T.S. Racie, B. Bramlage, A. Akinc, D. Butler, K. Charisse, R. Dorkin, and Y. Fan Therapeutic RNAi targeting PCSK9 acutely lowers plasma cholesterol in rodents and LDL cholesterol in nonhuman primates PNAS. 105 33 2008 11915 11920
8. S. Han, A.M. Flattery, D. McLaren, R. Raubertas, S.H. Lee, V. Mendoza, R. Rosa, N. Geoghagen, J.M. Castro-Perez, T.P. Roddy, G. Forrest, D.G. Johns, B.K. Hubbard, and J. Li Comparison of lipoprotein separation and lipid analysis methodologies for human and cynomolgus monkey plasma samples J. Cardiovasc. Transl. Res. 5 2012 75 83
9. M. Hultin, C. Carneheim, K. Rosenqvist, and T. Olivecrona Intravenous lipid emulsions: removal mechanisms as compared to chylomicrons J. Lipid Res. 36 1995 2174 2184
10. E.S. Istvan, and J. Deisenhofer Structural mechanism for statin inhibition of HMG-CoA reductase Science 292 2001 1160 1164
11. 2O quantification Am. J. Physiol.: Endocrinol. Metab. 302 2012 E209 E217
12. R.J. Konrad, J.S. Troutt, and G. Cao Effects of currently prescribed LDL-C-lowering drugs on PCSK9 and implications for the next generation of LDL-C-lowering agents Lipids Health Dis. 10 2011 38
13. R. Krishna, M.S. Anderson, A.J. Bergman, B. Jin, M. Fallon, J. Cote, K. Rosko, C. Chavez-Eng, R. Lutz, D.M. Bloomfield, M. Gutierrez, J. Doherty, F. Bieberdorf, J. Chodakewitz, K.M. Gottesdiener, and J.A. Wagner Effect of the cholesteryl ester transfer protein inhibitor, anacetrapib, on lipoproteins in patients with dyslipidaemia and on 24-h ambulatory blood pressure in healthy individuals: two double-blind, randomised placebo-controlled phase I studies Lancet 370 2007 1907 1914
14. M.E. Lassman, T.M. McLaughlin, E.P. Somers, A.C. Stefanni, Z. Chen, B.A. Murphy, K.K. Bierilo, A.M. Flattery, K.K. Wong, J.M. Castro-Perez, B.K. Hubbard, and T.P. Roddy A rapid method for cross-species quantitation of apolipoproteins A1, B48 and B100 in plasma by ultra-performance liquid chromatography/tandem mass spectrometry Rapid Commun. Mass Spectrom. 26 2012 101 108
15. S.J. Nicholls, H.B. Brewer, J.J.P. Kastelein, K.A. Krueger, M.-D. Wang, M. Shao, B. Hu, E. McErlean, and S.E. Nissen Effects of the CETP inhibitor evacetrapib administered as monotherapy or in combination with statins on HDL and LDL cholesterol: a randomized controlled trial J. Am. Med. Assoc. 306 2011 2099 2109
16. M. Ranalletta, K.K. Bierilo, Y. Chen, D. Milot, Q. Chen, E. Tung, C. Houde, N.H. Elowe, M. Garcia-Calvo, G. Porter, S. Eveland, B. Frantz-Wattley, M. Kavana, G. Addona, P. Sinclair, C.P. Sparrow, E.A. O'Neill, K.S. Koblan, A. Sitlani, B. Hubbard, and T.S. Fisher Biochemical characterization of cholesteryl ester transfer protein inhibitors J. Lipid Res. 51 2010 2739 2752
17. G.G. Schwartz, A.G. Olsson, M. Abt, C.M. Ballantyne, P.J. Barter, J. Brumm, B.R. Chaitman, I.M. Holme, D. Kallend, L.A. Leiter, E. Leitersdorf, J.J.V. McMurray, H. Mundl, S.J. Nicholls, P.K. Shah, J.-C. Tardif, and R.S. Wright Effects of dalcetrapib in patients with a recent acute coronary syndrome N. Engl. J. Med. 367 2012 2089 2099
18. S.-P. Wang, E. Daniels, Y. Chen, J. Castro-Perez, H. Zhou, K.O. Akinsanya, S.F. Previs, T.P. Roddy, and D.G. Johns in vivo effects of anacetrapib on pre-beta HDL: improvement in HDL remodeling without effects on cholesterol absorption J. Lipid Res. 54 2013 2858 2865
19. W. Yin, E. Carballo-Jane, D.G. McLaren, V.H. Mendoza, K. Gagen, N.S. Geoghagen, L.A. McNamara, J.N. Gorski, G.J. Eiermann, A. Petrov, M. Wolff, X. Tong, L.C. Wilsie, T.E. Akiyama, J. Chen, A. Thankappan, J. Xue, X. Ping, G. Andrews, L.A. Wickham, C.L. Gai, T. Trinh, A.A. Kulick, M.J. Donnelly, G.O. Voronin, R. Rosa, A.-M. Cumiskey, K.B. Bekkari, L.J. Mitnaul, O. Puig, F. Chen, R. Raubertas, P.H. Wong, B.C. Hansen, K.S. Koblan, T.P. Roddy, B.K. Hubbard, and A.M. Strack Plasma lipid profiling across species for the identification of optimal animal models of human dyslipidemia J. Lipid Res. 53 2012 51 65
20. L. Zhang, T. McCabe, J.H. Condra, Y.G. Ni, L.B. Peterson, W. Wang, A.M. Strack, F. Wang, S. Pandit, H. Hammond, D. Wood, D. Lewis, R. Rosa, V. Mendoza, A.M. Cumiskey, D.G. Johns, B.C. Hansen, X. Shen, N. Geoghagen, K. Jensen, L. Zhu, K. Wietecha, D. Wisniewski, L. Huang, J.Z. Zhao, R. Ernst, R. Hampton, P. Haytko, F. Ansbro, S. Chilewski, J. Chin, L.J. Mitnaul, A. Pellacani, C.P. Sparrow, Z. An, W. Strohl, B. Hubbard, A.S. Plump, D. Blom, and A. Sitlani An anti-PCSK9 antibody reduces LDL-cholesterol on top of a statin and suppresses hepatocyte SREBP-regulated genes Int. J. Biol. Sci. 8 2012 310